Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1809, Issue 2, 2011, Pages 128-140

  Hegde, Ashok N ^a   Upadhya, Sudarshan C ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

Alzheimer's; Mental disorders; Neurodegenerative disease; Parkinson's; Synaptic plasticity; Therapeutic targets

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; PROTEASOME; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN CONJUGATING ENZYME E1; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN CONJUGATING ENZYME E3; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ATAXIA; AUTOPHAGY; CONJUGATION; GENETIC TRANSCRIPTION; HAPPY PUPPET SYNDROME; HUMAN; HUNTINGTON CHOREA; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; REVIEW; RING FINGER MOTIF;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; NERVOUS SYSTEM DISEASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 79151485014     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2010.07.006     Document Type: Review

References (204)

1. de Vrij F.M., Fischer D.F., van Leeuwen F.W., Hol E.M. Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Prog. Neurobiol. 2004, 74:249-270.
2. Upadhya S.C., Hegde A.N. Ubiquitin-proteasome pathway components as therapeutic targets for CNS maladies. Curr. Pharm. Des. 2005, 11:3807-3828.
3. Rubinsztein D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443:780-786.
4. Upadhya S.C., Hegde A.N. Role of the ubiquitin proteasome system in Alzheimer's disease. BMC Biochem. 2007, 8(Suppl 1):S12.
5. Mori H., Kondo J., Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 1987, 235:1641-1644.
6. Lowe J., Blanchard A., Morrell K., Lennox G., Reynolds L., Billett M., Landon M., Mayer R.J. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J. Pathol. 1988, 155:9-15.
7. Hegde A.N. Ubiquitin-proteasome-mediated local protein degradation and synaptic plasticity. Prog. Neurobiol. 2004, 73:311-357.
8. Tai H.C., Schuman E.M. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat. Rev. Neurosci. 2008, 9:826-838.
9. Hershko A., Heller H., Elias S., Ciechanover A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J. Biol. Chem. 1983, 258:8206-8214.
10. Deng L., Wang C., Spencer E., Yang L., Braun A., You J., Slaughter C., Pickart C., Chen Z.J. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000, 103:351-361.
11. Komander D. The emerging complexity of protein ubiquitination. Biochem. Soc. Trans. 2009, 37:937-953.
12. Ye Y., Rape M. Building ubiquitin chains: E2 enzymes at work. Nat. Rev. Mol. Cell Biol. 2009, 10:755-764.
13. Glickman M.H., Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 2002, 82:373-428.
14. Hegde A.N. Ubiquitin-Dependent Protein Degradation. Comprehensive Natural Products II Chemistry and Biology 2010, vol. 5:699-752. Elsevier, Oxford.
15. Reyes-Turcu F.E., Wilkinson K.D. Polyubiquitin binding and disassembly by deubiquitinating enzymes. Chem. Rev. 2009, 109:1495-1508.
16. Nagy V., Dikic I. Ubiquitin ligase complexes: from substrate selectivity to conjugational specificity. Biol. Chem. 2010, 391:163-169.
17. Beer-Romero P., Glass S., Rolfe M. Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene 1997, 14:595-602.
18. Colledge M., Snyder E.M., Crozier R.A., Soderling J.A., Jin Y., Langeberg L.K., Lu H., Bear M.F., Scott J.D. Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression. Neuron 2003, 40:595-607.
19. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
20. Petroski M.D., Deshaies R.J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 2005, 6:9-20.
21. Tanaka K., Kawakami T., Tateishi K., Yashiroda H., Chiba T. Control of IkappaBalpha proteolysis by the ubiquitin-proteasome pathway. Biochimie 2001, 83:351-356.
22. Hershko A. Mechanisms and regulation of the degradation of cyclin B. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1999, 354:1571-1575.
23. Fang G., Yu H., Kirschner M.W. Control of mitotic transitions by the anaphase-promoting complex. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1999, 354:1583-1590.
24. Cheng Y. Toward an atomic model of the 26S proteasome. Curr. Opin. Struct. Biol. 2009, 19:203-208.
25. Marques A.J., Palanimurugan R., Matias A.C., Ramos P.C., Dohmen R.J. Catalytic mechanism and assembly of the proteasome. Chem. Rev. 2009, 109:1509-1536.
26. Gallastegui N., Groll M. The 26S proteasome: assembly and function of a destructive machine. Trends Biochem. Sci. 2010, Epub ahead of print.
27. Leggett D.S., Hanna J., Borodovsky A., Crosas B., Schmidt M., Baker R.T., Walz T., Ploegh H., Finley D. Multiple associated proteins regulate proteasome structure and function. Mol. Cell 2002, 10:495-507.
28. Peth A., Besche H.C., Goldberg A.L. Ubiquitinated proteins activate the proteasome by binding to Usp14/Ubp6, which causes 20S gate opening. Mol. Cell 2009, 36:794-804.
29. Wilkinson K.D. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin. Cell Dev. Biol. 2000, 11:141-148.
30. Baker R.T., Board P.G. The human ubiquitin gene family: structure of a gene and pseudogenes from the Ub B subfamily. Nucleic Acids Res. 1987, 15:443-463.
31. Baker R.T., Board P.G. The human ubiquitin-52 amino acid fusion protein gene shares several structural features with mammalian ribosomal protein genes. Nucleic Acids Res. 1991, 19:1035-1040.
32. Hegde A.N., Goldberg A.L., Schwartz J.H. Regulatory subunits of cAMP-dependent protein kinases are degraded after conjugation to ubiquitin: a molecular mechanism underlying long-term synaptic plasticity. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:7436-7440.
33. Greenberg S.M., Castellucci V.F., Bayley H., Schwartz J.H. A molecular mechanism for long-term sensitization in Aplysia. Nature 1987, 329:62-65.
34. Hegde A.N., Inokuchi K., Pei W., Casadio A., Ghirardi M., Chain D.G., Martin K.C., Kandel E.R., Schwartz J.H. Ubiquitin C-terminal hydrolase is an immediate-early gene essential for long-term facilitation in Aplysia. Cell 1997, 89:115-126.
35. Gong B., Cao Z., Zheng P., Vitolo O.V., Liu S., Staniszewski A., Moolman D., Zhang H., Shelanski M., Arancio O. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 2006, 126:775-788.
36. Chain D.G., Casadio A., Schacher S., Hegde A.N., Valbrun M., Yamamoto N., Goldberg A.L., Bartsch D., Kandel E.R., Schwartz J.H. Mechanisms for generating the autonomous cAMP-dependent protein kinase required for long-term facilitation in Aplysia. Neuron 1999, 22:147-156.
37. The ubiquitin-proteasome cascade is required for mammalian long-term memory formation. Eur. J. Neurosci. 2001, 14:1820-1826.
38. Lee S.H., Choi J.H., Lee N., Lee H.R., Kim J.I., Yu N.K., Choi S.L., Lee S.H., Kim H., Kaang B.K. Synaptic protein degradation underlies destabilization of retrieved fear memory. Science 2008, 319:1253-1256.
39. Hegde A.N. The ubiquitin-proteasome pathway and synaptic plasticity. Learn. Mem. 2010, 17:314-327.
40. Dash P.K., Hochner B., Kandel E.R. Injection of the cAMP-responsive element into the nucleus of Aplysia sensory neurons blocks long-term facilitation. Nature 1990, 345:718-721.
41. Bourtchuladze R., Frenguelli B., Blendy J., Cioffi D., Schutz G., Silva A.J. Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. Cell 1994, 79:59-68.
42. Yin J.C., Wallach J.S., Del V.M., Wilder E.L., Zhou H., Quinn W.G., Tully T. Induction of a dominant negative CREB transgene specifically blocks long-term memory in Drosophila. Cell 1994, 79:49-58.
43. Bartsch D., Casadio A., Karl K.A., Serodio P., Kandel E.R. CREB1 encodes a nuclear activator, a repressor, and a cytoplasmic modulator that form a regulatory unit critical for long-term facilitation. Cell 1998, 95:211-223.
44. Habener J.F., Miller C.P., Vallejo M. cAMP-dependent regulation of gene transcription by cAMP response element-binding protein and cAMP response element modulator. Vitam. Horm. 1995, 51:1-57.
45. Sassone-Corsi P. Transcription factors responsive to cAMP. Annu. Rev. Cell Dev. Biol. 1995, 11:355-377.
46. Upadhya S.C., Smith T.K., Hegde A.N. Ubiquitin-proteasome-mediated CREB repressor degradation during induction of long-term facilitation. J. Neurochem. 2004, 91:210-219.
47. Yamamoto N., Hegde A.N., Chain D.G., Schwartz J.H. Activation and degradation of the transcription factor C/EBP during long-term facilitation in Aplysia. J. Neurochem. 1999, 73:2415-2423.
48. Dong C., Upadhya S.C., Ding L., Smith T.K., Hegde A.N. Proteasome inhibition enhances the induction and impairs the maintenance of late-phase long-term potentiation. Learn. Mem. 2008, 15:335-347.
49. Gonzalez F., Delahodde A., Kodadek T., Johnston S.A. Recruitment of a 19S proteasome subcomplex to an activated promoter. Science 2002, 296:548-550.
50. Hegde A.N., Upadhya S.C. Proteasome and transcription: a destroyer goes into construction. Bioessays 2006, 28:235-239.
51. Geiss-Friedlander R., Melchior F. Concepts in sumoylation: a decade on. Nat. Rev. Mol. Cell Biol. 2007, 8:947-956.
52. Lyst M.J., Stancheva I. A role for SUMO modification in transcriptional repression and activation. Biochem. Soc. Trans. 2007, 35:1389-1392.
53. Cohen-Cory S. The developing synapse: construction and modulation of synaptic structures and circuits. Science 2002, 298:770-776.
54. Stegmuller J., Konishi Y., Huynh M.A., Yuan Z., Dibacco S., Bonni A. Cell-intrinsic regulation of axonal morphogenesis by the Cdh1-APC target SnoN. Neuron 2006, 50:389-400.
55. Layfield R., Cavey J.R., Lowe J. Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. Ageing Res. Rev. 2003, 2:343-356.
56. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
57. Bingol B., Schuman E.M. Synaptic protein degradation by the ubiquitin proteasome system. Curr. Opin. Neurobiol. 2005, 15:536-541.
58. Patrick G.N. Synapse formation and plasticity: recent insights from the perspective of the ubiquitin proteasome system. Curr. Opin. Neurobiol. 2006, 16:90-94.
59. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-414.
60. Graeber M.B., Kosel S., Egensperger R., Banati R.B., Muller U., Bise K., Hoff P., Moller H.J., Fujisawa K., Mehraein P. Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis. Neurogenetics 1997, 1:73-80.
61. Moller H.J., Graeber M.B. The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur. Arch. Psychiatry Clin. Neurosci. 1911, 248(1998):111-122.
62. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
63. Perry G., Rizzuto N., Utilio-Gambetti L., Gambetti P. Paired helical filaments from Alzheimer disease patients contain cytoskeletal components. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:3916-3920.
64. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
65. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
66. Iwata N., Higuchi M., Saido T.C. Metabolism of amyloid-beta peptide and Alzheimer's disease. Pharmacol. Ther. 2005, 108:129-148.
67. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:4245-4249.
68. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
69. An W.L., Cowburn R.F., Li L., Braak H., Alafuzoff I., Iqbal K., Iqbal I.G., Winblad B., Pei J.J. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am. J. Pathol. 2003, 163:591-607.
70. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
71. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
72. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3228-3233.
73. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
74. Larson J., Lynch G., Games D., Seubert P. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res. 1999, 840:23-35.
75. Moechars D., Dewachter I., Lorent K., Reverse D., Baekelandt V., Naidu A., Tesseur I., Spittaels K., Van Den Haute C., Checler F., Godaux E., Cordell B., Van Leuven F. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 1999, 274:6483-6492.
76. Vitolo O.V., Sant'Angelo A., Costanzo V., Battaglia F., Arancio O., Shelanski M. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13217-13221.
77. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
78. Chapman P.F., White G.L., Jones M.W., Cooper-Blacketer D., Marshall V.J., Irizarry M., Younkin L., Good M.A., Bliss T.V.P., Hyman B.T., Younkin S.G., Hsiao K.K. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 1999, 2:271-276.
79. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
80. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
81. Ciechanover A., Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003, 40:427-446.
82. Mayer R.J., Tipler C., Arnold J., Laszlo L., Al-Khedhairy A., Lowe J., Landon M. Endosome-lysosomes, ubiquitin and neurodegeneration. Adv. Exp. Med. Biol. 1996, 389:261-269.
83. Busciglio J., Hartmann H., Lorenzo A., Wong C., Baumann K., Sommer B., Staufenbiel M., Yankner B.A. Neuronal localization of presenilin-1 and association with amyloid plaques and neurofibrillary tangles in Alzheimer's disease. J. Neurosci. 1997, 17:5101-5107.
84. Chui D.H., Shirotani K., Tanahashi H., Akiyama H., Ozawa K., Kunishita T., Takahashi K., Makifuchi T., Tabira T. Both N-terminal and C-terminal fragments of presenilin 1 colocalize with neurofibrillary tangles in neurons and dystrophic neurites of senile plaques in Alzheimer's disease. J. Neurosci. Res. 1998, 53:99-106.
85. Lowe J. Establishing a pathological diagnosis in degenerative dementias. Brain Pathol. 1998, 8:403-406.
86. Checler F., da Costa C.A., Ancolio K., Chevallier N., Lopez-Perez E., Marambaud P. Role of the proteasome in Alzheimer's disease. Biochim. Biophys. Acta 2000, 1502:133-138.
87. Dil K.A., Kito K., Abe Y., Shin R.W., Kamitani T., Ueda N. NEDD8 protein is involved in ubiquitinated inclusion bodies. J. Pathol. 2003, 199:259-266.
88. Paine S., Bedford L., Thorpe J.R., Mayer R.J., Cavey J.R., Bajaj N., Sheppard P.W., Lowe J., Layfield R. Immunoreactivity to Lys63-linked polyubiquitin is a feature of neurodegeneration. Neurosci. Lett. 2009, 460:205-208.
89. Perry G., Friedman R., Shaw G., Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:3033-3036.
90. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl) 1991, 82:239-259.
91. Arnaud L., Robakis N.K., Figueiredo-Pereira M.E. It may take inflammation, phosphorylation and ubiquitination to 'tangle' in Alzheimer's disease. Neurodegener. Dis. 2006, 3:313-319.
92. Johnston J.A., Ward C.L., Kopito R.R. Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 1998, 143:1883-1898.
93. Li Z., Arnaud L., Rockwell P., Figueiredo-Pereira M.E. A single amino acid substitution in a proteasome subunit triggers aggregation of ubiquitinated proteins in stressed neuronal cells. J. Neurochem. 2004, 90:19-28.
94. Smith D.L., Pozueta J., Gong B., Arancio O., Shelanski M. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16877-16882.
95. Ichihara N., Wu J., Chui D.H., Yamazaki K., Wakabayashi T., Kikuchi T. Axonal degeneration promotes abnormal accumulation of amyloid beta-protein in ascending gracile tract of gracile axonal dystrophy (GAD) mouse. Brain Res. 1995, 695:173-178.
96. Wu J., Ichihara N., Chui D.H., Yamazaki K., Kikuchi T. Ubiquitin immunoreactivity in the central nervous system of gracile axonal dystrophy (GAD) mouse. No To Shinkei 1995, 47:881-885.
97. Osaka H., Wang Y.L., Takada K., Takizawa S., Setsuie R., Li H., Sato Y., Nishikawa K., Sun Y.J., Sakurai M., Harada T., Hara Y., Kimura I., Chiba S., Namikawa K., Kiyama H., Noda M., Aoki S., Wada K. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum. Mol. Genet. 2003, 12:1945-1958.
98. Barrachina M., Castano E., Dalfo E., Maes T., Buesa C., Ferrer I. Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies. Neurobiol. Dis. 2006, 22:265-273.
99. Choi J., Levey A.I., Weintraub S.T., Rees H.D., Gearing M., Chin L.S., Li L. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 2004, 279:13256-13264.
100. Xue S., Jia J. Genetic association between ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism and sporadic Alzheimer's disease in a Chinese Han population. Brain Res. 2006, 1087:28-32.
101. Fischer D.F., van D.R., van T.P., Hobo B., Verhage M.C., van der Schors R.C., Li K.W., van M.J., Hol E.M., van Leeuwen F.W. Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin. Neurobiol. Aging 2009, 30:847-863.
102. Wang L.N., Zhu M.W., Gui Q.P., Li X.H. An analysis of the causes of dementia in 383 elderly autopsied cases. Zhonghua Nei Ke Za Zhi 2003, 42:789-792.
103. van Leeuwen F.W., van T.P., Sonnemans M.A., Hobo B., Mann D.M., van B.C., Kumar-Singh S., Cras P., Leuba G., Savioz A., Maat-Schieman M.L., Yamaguchi H., Kros J.M., Kamphorst W., Hol E.M., de Vos R.A., Fischer D.F. Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies. Neurology 2006, 66:S86-S92.
104. Forman M.S., Farmer J., Johnson J.K., Clark C.M., Arnold S.E., Coslett H.B., Chatterjee A., Hurtig H.I., Karlawish J.H., Rosen H.J., Van D., Lee V.V.M., Miller B.L., Trojanowski J.Q., Grossman M. Frontotemporal dementia: clinicopathological correlations. Ann. Neurol. 2006, 59:952-962.
105. Song S., Kim S.Y., Hong Y.M., Jo D.G., Lee J.Y., Shim S.M., Chung C.W., Seo S.J., Yoo Y.J., Koh J.Y., Lee M.C., Yates A.J., Ichijo H., Jung Y.K. Essential role of E2-25K/Hip-2 in mediating amyloid-beta neurotoxicity. Mol. Cell 2003, 12:553-563.
106. Song S., Lee H., Kam T.I., Tai M.L., Lee J.Y., Noh J.Y., Shim S.M., Seo S.J., Kong Y.Y., Nakagawa T., Chung C.W., Choi D.Y., Oubrahim H., Jung Y.K. E2-25K/Hip-2 regulates caspase-12 in ER stress-mediated Abeta neurotoxicity. J. Cell Biol. 2008, 182:675-684.
107. Shringarpure R., Grune T., Sitte N., Davies K.J. 4-Hydroxynonenal-modified amyloid-beta peptide inhibits the proteasome: possible importance in Alzheimer's disease. Cell. Mol. Life Sci. 2000, 57:1802-1809.
108. Gregori L., Hainfeld J.F., Simon M.N., Goldgaber D. Binding of amyloid beta protein to the 20S proteasome. J. Biol. Chem. 1997, 272:58-62.
109. Almeida C.G., Takahashi R.H., Gouras G.K. Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J. Neurosci. 2006, 26:4277-4288.
110. Wirths O., Weis J., Kayed R., Saido T.C., Bayer T.A. Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiol. Aging 2007, 28:1689-1699.
111. Wirths O., Weis J., Szczygielski J., Multhaup G., Bayer T.A. Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer's disease. Acta Neuropathol. (Berl) 2006, 111:312-319.
112. Keller J.N., Hanni K.B., Markesbery W.R. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 2000, 75:436-439.
113. Keck S., Nitsch R., Grune T., Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J. Neurochem. 2003, 85:115-122.
114. Bossy-Wetzel E., Schwarzenbacher R., Lipton S.A. Molecular pathways to neurodegeneration. Nat. Med. 2004, 10(Suppl):S2-S9.
115. Dickey C.A., Yue M., Lin W.L., Dickson D.W., Dunmore J.H., Lee W.C., Zehr C., West G., Cao S., Clark A.M., Caldwell G.A., Caldwell K.A., Eckman C., Patterson C., Hutton M., Petrucelli L. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J. Neurosci. 2006, 26:6985-6996.
116. Sahara N., Murayama M., Mizoroki T., Urushitani M., Imai Y., Takahashi R., Murata S., Tanaka K., Takashima A. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J. Neurochem. 2005, 94:1254-1263.
117. Babu J.R., Geetha T., Wooten M.W. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J. Neurochem. 2005, 94:192-203.
118. van Leeuwen F.W., de Kleijn D.P., van den Hurk H.H., Neubauer A., Sonnemans M.A., Sluijs J.A., Koycu S., Ramdjielal R.D., Salehi A., Martens G.J., Grosveld F.G., Peter J., Burbach H., Hol E.M. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 1998, 279:242-247.
119. Lam Y.A., Pickart C.M., Alban A., Landon M., Jamieson C., Ramage R., Mayer R.J., Layfield R. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:9902-9906.
120. van T.P., de Vrij F.M., Schuurman K.G., Dantuma N.P., Fischer D.F., van Leeuwen F.W., Hol E.M. Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease. J. Cell Sci. 2007, 120:1615-1623.
121. de P.R., Fischer D.F., Maat-Schieman M.L., Hobo B., de Vos R.A., Brunt E.R., Hol E.M., Roos R.A., van Leeuwen F.W. Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum. Mol. Genet. 2004, 13:1803-1813.
122. Lindsten K., de Vrij F.M., Verhoef L.G., Fischer D.F., van Leeuwen F.W., Hol E.M., Masucci M.G., Dantuma N.P. Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J. Cell Biol. 2002, 157:417-427.
123. Kim T.W., Pettingell W.H., Hallmark O.G., Moir R.D., Wasco W., Tanzi R.E. Endoproteolytic cleavage and proteasomal degradation of presenilin 2 in transfected cells. J. Biol. Chem. 1997, 272:11006-11010.
124. Hoffman E.K., Wilcox H.M., Scott R.W., Siman R. Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis. J. Neurol. Sci. 1996, 139:15-20.
125. Johnston J.A., Dalton M.J., Gurney M.E., Kopito R.R. Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12571-12576.
126. Niwa J., Ishigaki S., Hishikawa N., Yamamoto M., Doyu M., Murata S., Tanaka K., Taniguchi N., Sobue G. Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity. J. Biol. Chem. 2002, 277:36793-36798.
127. Miyazaki K., Fujita T., Ozaki T., Kato C., Kurose Y., Sakamoto M., Kato S., Goto T., Itoyama Y., Aoki M., Nakagawara A. NEDL1, a novel ubiquitin-protein isopeptide ligase for dishevelled-1, targets mutant superoxide dismutase-1. J. Biol. Chem. 2004, 279:11327-11335.
128. Di N.L., Whitson L.J., Cao X., Hart P.J., Levine R.L. Proteasomal degradation of mutant superoxide dismutases linked to amyotrophic lateral sclerosis. J. Biol. Chem. 2005, 280:39907-39913.
129. Kabuta T., Suzuki Y., Wada K. Degradation of amyotrophic lateral sclerosis-linked mutant Cu, Zn-superoxide dismutase proteins by macroautophagy and the proteasome. J. Biol. Chem. 2006, 281:30524-30533.
130. Ishigaki S., Niwa J., Ando Y., Yoshihara T., Sawada K., Doyu M., Yamamoto M., Kato K., Yotsumoto Y., Sobue G. Differentially expressed genes in sporadic amyotrophic lateral sclerosis spinal cords-screening by molecular indexing and subsequent cDNA microarray analysis. FEBS Lett. 2002, 531:354-358.
131. Urushitani M., Kurisu J., Tateno M., Hatakeyama S., Nakayama K., Kato S., Takahashi R. CHIP promotes proteasomal degradation of familial ALS-linked mutant SOD1 by ubiquitinating Hsp/Hsc70. J. Neurochem. 2004, 90:231-244.
132. Urushitani M., Kurisu J., Tsukita K., Takahashi R. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J. Neurochem. 2002, 83:1030-1042.
133. Lee J.P., Gerin C., Bindokas V.P., Miller R., Ghadge G., Roos R.P. No correlation between aggregates of Cu/Zn superoxide dismutase and cell death in familial amyotrophic lateral sclerosis. J. Neurochem. 2002, 82:1229-1238.
134. Vlug A.S., Jaarsma D. Long term proteasome inhibition does not preferentially afflict motor neurons in organotypical spinal cord cultures. Amyotroph. Lateral. Scler. 2004, 5:16-21.
135. Aquilano K., Rotilio G., Ciriolo M.R. Proteasome activation and nNOS down-regulation in neuroblastoma cells expressing a Cu, Zn superoxide dismutase mutant involved in familial ALS. J. Neurochem. 2003, 85:1324-1335.
136. Hyun D.H., Lee M., Halliwell B., Jenner P. Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins. J. Neurochem. 2003, 86:363-373.
137. Cheroni C., Marino M., Tortarolo M., Veglianese P., De B.S., Fontana E., Zuccarello L.V., Maynard C.J., Dantuma N.P., Bendotti C. Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis. Hum. Mol. Genet. 2009, 18:82-96.
138. Wang I.F., Wu L.S., Shen C.K. TDP-43: an emerging new player in neurodegenerative diseases. Trends Mol. Med. 2008, 14:479-485.
139. Buratti E., Baralle F.E. The molecular links between TDP-43 dysfunction and neurodegeneration. Adv. Genet. 2009, 66:1-34.
140. Williams C.A. Neurological aspects of the Angelman syndrome. Brain Dev. 2005, 27:88-94.
141. Kishino T., Lalande M., Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. Nat. Genet. 1997, 15:70-73.
142. Matsuura T., Sutcliffe J.S., Fang P., Galjaard R.J., Jiang Y.H., Benton C.S., Rommens J.M., Beaudet A.L. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat. Genet. 1997, 15:74-77.
143. Jiang Y.H., Armstrong D., Albrecht U., Atkins C.M., Noebels J.L., Eichele G., Sweatt J.D., Beaudet A.L. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 1998, 21:799-811.
144. Albrecht U., Sutcliffe J.S., Cattanach B.M., Beechey C.V., Armstrong D., Eichele G., Beaudet A.L. Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat. Genet. 1997, 17:75-78.
145. Rougeulle C., Glatt H., Lalande M. The Angelman syndrome candidate gene, UBE3A/E6-AP, is imprinted in brain. Nat. Genet. 1997, 17:14-15.
146. Huibregtse J.M., Scheffner M., Howley P.M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 1991, 10:4129-4135.
147. Kumar S., Talis A.L., Howley P.M. Identification of HHR23A as a substrate for E6-associated protein-mediated ubiquitination. J. Biol. Chem. 1999, 274:18785-18792.
148. Kuhne C., Banks L. E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J. Biol. Chem. 1998, 273:34302-34309.
149. Nuber U., Schwarz S.E., Scheffner M. The ubiquitin-protein ligase E6-associated protein (E6-AP) serves as its own substrate. Eur. J. Biochem. 1998, 254:643-649.
150. Weeber E.J., Jiang Y.H., Elgersma Y., Varga A.W., Carrasquillo Y., Brown S.E., Christian J.M., Mirnikjoo B., Silva A., Beaudet A.L., Sweatt J.D. Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome. J. Neurosci. 2003, 23:2634-2644.
151. van Woerden G.M., Harris K.D., Hojjati M.R., Gustin R.M., Qiu S., de Avila F.R., Jiang Y.H., Elgersma Y., Weeber E.J. Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation. Nat. Neurosci. 2007, 10:280-282.
152. Greer P.L., Hanayama R., Bloodgood B.L., Mardinly A.R., Lipton D.M., Flavell S.W., Kim T.K., Griffith E.C., Waldon Z., Maehr R., Ploegh H.L., Chowdhury S., Worley P.F., Steen J., Greenberg M.E. The Angelman syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell 2010, 140:704-716.
153. Wilson S.M., Bhattacharyya B., Rachel R.A., Coppola V., Tessarollo L., Householder D.B., Fletcher C.F., Miller R.J., Copeland N.G., Jenkins N.A. Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat. Genet. 2002, 32:420-425.
154. Anderson C., Crimmins S., Wilson J.A., Korbel G.A., Ploegh H.L., Wilson S.M. Loss of Usp14 results in reduced levels of ubiquitin in ataxia mice. J. Neurochem. 2005, 95:724-731.
155. Crimmins S., Jin Y., Wheeler C., Huffman A.K., Chapman C., Dobrunz L.E., Levey A., Roth K.A., Wilson J.A., Wilson S.M. Transgenic rescue of ataxia mice with neuronal-specific expression of ubiquitin-specific protease 14. J. Neurosci. 2006, 26:11423-11431.
156. Chen P.C., Qin L.N., Li X.M., Walters B.J., Wilson J.A., Mei L., Wilson S.M. The proteasome-associated deubiquitinating enzyme Usp14 is essential for the maintenance of synaptic ubiquitin levels and the development of neuromuscular junctions. J. Neurosci. 2009, 29:10909-10919.
157. Mohr E., Brouwers P., Claus J.J., Mann U.M., Fedio P., Chase T.N. Visuospatial cognition in Huntington's disease. Mov Disord. 1991, 6:127-132.
158. Foroud T., Siemers E., Kleindorfer D., Bill D.J., Hodes M.E., Norton J.A., Conneally P.M., Christian J.C. Cognitive scores in carriers of Huntington's disease gene compared to noncarriers. Ann. Neurol. 1995, 37:657-664.
159. Lange K.W., Sahakian B.J., Quinn N.P., Marsden C.D., Robbins T.W. Comparison of executive and visuospatial memory function in Huntington's disease and dementia of Alzheimer type matched for degree of dementia. J. Neurol. Neurosurg. Psychiatry 1995, 58:598-606.
160. Lawrence A.D., Sahakian B.J., Hodges J.R., Rosser A.E., Lange K.W., Robbins T.W. Executive and mnemonic functions in early Huntington's disease. Brain 1996, 119(Pt 5):1633-1645.
161. Lawrence A.D., Hodges J.R., Rosser A.E., Kershaw A., ffrench-Constant C., Rubinsztein D.C., Robbins T.W., Sahakian B.J. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998, 121(Pt 7):1329-1341.
162. Murphy K.P., Carter R.J., Lione L.A., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J. Neurosci. 2000, 20:5115-5123.
163. Shelbourne P.F., Killeen N., Hevner R.F., Johnston H.M., Tecott L., Lewandoski M., Ennis M., Ramirez L., Li Z., Iannicola C., Littman D.R., Myers R.M. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum. Mol. Genet. 1999, 8:763-774.
164. Morton A.J., Faull R.L., Edwardson J.M. Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease. Brain Res. Bull. 2001, 56:111-117.
165. Lee J.A., Lim C.S., Lee S.H., Kim H., Nukina N., Kaang B.K. Aggregate formation and the impairment of long-term synaptic facilitation by ectopic expression of mutant huntingtin in Aplysia neurons. J. Neurochem. 2003, 85:160-169.
166. Jana N.R., Zemskov E.A., Wang G., Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet. 2001, 10:1049-1059.
167. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
168. Bennett E.J., Shaler T.A., Woodman B., Ryu K.Y., Zaitseva T.S., Becker C.H., Bates G.P., Schulman H., Kopito R.R. Global changes to the ubiquitin system in Huntington's disease. Nature 2007, 448:704-708.
169. Martin-Aparicio E., Yamamoto A., Hernandez F., Hen R., Avila J., Lucas J.J. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J. Neurosci. 2001, 21:8772-8781.
170. Ding Q., Lewis J.J., Strum K.M., Dimayuga E., Bruce-Keller A.J., Dunn J.C., Keller J.N. Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival. J. Biol. Chem. 2002, 277:13935-13942.
171. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 1998, 395:451-452.
172. Polymeropoulos M.H. Genetics of Parkinson's disease. Ann. N. Y. Acad. Sci. 2000, 920:28-32.
173. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299:256-259.
174. Cookson M.R. Pathways to Parkinsonism. Neuron 2003, 37:7-10.
175. Shinbo Y., Niki T., Taira T., Ooe H., Takahashi-Niki K., Maita C., Seino C., Iguchi-Ariga S.M., Ariga H. Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell Death. Differ. 2006, 13:96-108.
176. Lotharius J., Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 2002, 3:932-942.
177. Goldberg M.S., Fleming S.M., Palacino J.J., Cepeda C., Lam H.A., Bhatnagar A., Meloni E.G., Wu N., Ackerson L.C., Klapstein G.J., Gajendiran M., Roth B.L., Chesselet M.F., Maidment N.T., Levine M.S., Shen J. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 2003, 278:43628-43635.
178. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 2000, 25:302-305.
179. Huynh D.P., Scoles D.R., Nguyen D., Pulst S.M. The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum. Mol. Genet. 2003, 12:2587-2597.
180. Lim K.L., Dawson V.L., Dawson T.M. Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases?. Neurobiol. Aging 2006, 27:524-529.
181. Olzmann J.A., Chin L.S. Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway. Autophagy 2008, 4:85-87.
182. Chin L.S., Olzmann J.A., Li L. Parkin-mediated ubiquitin signalling in aggresome formation and autophagy. Biochem. Soc. Trans. 2010, 38:144-149.
183. Tsai Y.C., Fishman P.S., Thakor N.V., Oyler G.A. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem. 2003, 278:22044-22055.
184. Morishima Y., Wang A.M., Yu Z., Pratt W.B., Osawa Y., Lieberman A.P. CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins. Hum. Mol. Genet. 2008, 17:3942-3952.
185. Winborn B.J., Travis S.M., Todi S.V., Scaglione K.M., Xu P., Williams A.J., Cohen R.E., Peng J., Paulson H.L. The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J. Biol. Chem. 2008, 283:26436-26443.
186. Todi S.V., Winborn B.J., Scaglione K.M., Blount J.R., Travis S.M., Paulson H.L. Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3. EMBO J. 2009, 28:372-382.
187. Olzmann J.A., Li L., Chin L.S. Aggresome formation and neurodegenerative diseases: therapeutic implications. Curr. Med. Chem. 2008, 15:47-60.
188. Buhmann C., Bussopulos A., Oechsner M. Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease. Mov Disord. 2003, 18:219-221.
189. Bedford L., Hay D., Devoy A., Paine S., Powe D.G., Seth R., Gray T., Topham I., Fone K., Rezvani N., Mee M., Soane T., Layfield R., Sheppard P.W., Ebendal T., Usoskin D., Lowe J., Mayer R.J. Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J. Neurosci. 2008, 28:8189-8198.
190. Wahl C., Kautzmann S., Krebiehl G., Strauss K., Woitalla D., Muller T., Bauer P., Riess O., Kruger R. A comprehensive genetic study of the proteasomal subunit S6 ATPase in German Parkinson's disease patients. J. Neural Transm. 2008, 115:1141-1148.
191. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., Ueno T., Koike M., Uchiyama Y., Kominami E., Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
192. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., Yokoyama M., Mishima K., Saito I., Okano H., Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
193. Ding W.X., Ni H.M., Gao W., Yoshimori T., Stolz D.B., Ron D., Yin X.M. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am. J. Pathol. 2007, 171:513-524.
194. Pandey U.B., Nie Z., Batlevi Y., McCray B.A., Ritson G.P., Nedelsky N.B., Schwartz S.L., DiProspero N.A., Knight M.A., Schuldiner O., Padmanabhan R., Hild M., Berry D.L., Garza D., Hubbert C.C., Yao T.P., Baehrecke E.H., Taylor J.P. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007, 447:859-863.
195. Bjorkoy G., Lamark T., Brech A., Outzen H., Perander M., Overvatn A., Stenmark H., Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J. Cell Biol. 2005, 171:603-614.
196. Zhai Q., Wang J., Kim A., Liu Q., Watts R., Hoopfer E., Mitchison T., Luo L., He Z. Involvement of the ubiquitin-proteasome system in the early stages of wallerian degeneration. Neuron 2003, 39:217-225.
197. Hoopfer E.D., McLaughlin T., Watts R.J., Schuldiner O., O'Leary D.D., Luo L. Wlds protection distinguishes axon degeneration following injury from naturally occurring developmental pruning. Neuron 2006, 50:883-895.
198. Marambaud P., Zhao H., Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem. 2005, 280:37377-37382.
199. van Leeuwen F.W., de Kleijn D.P., van den Hurk H.H., Neubauer A., Sonnemans M.A., Sluijs J.A., Koycu S., Ramdjielal R.D., Salehi A., Martens G.J., Grosveld F.G., Peter J., Burbach H., Hol E.M. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 1998, 279:242-247.
200. Saigoh K., Wang Y.L., Suh J.G., Yamanishi T., Sakai Y., Kiyosawa H., Harada T., Ichihara N., Wakana S., Kikuchi T., Wada K. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet. 1999, 23:47-51.
201. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
202. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001, 293:263-269.
203. Middleton F.A., Mirnics K., Pierri J.N., Lewis D.A., Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J. Neurosci. 2002, 22:2718-2729.
204. Altar C.A., Jurata L.W., Charles V., Lemire A., Liu P., Bukhman Y., Young T.A., Bullard J., Yokoe H., Webster M.J., Knable M.B., Brockman J.A. Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol. Psychiatry 2005, 58:85-96.